Anzeige
Mehr »
Mittwoch, 11.02.2026 - Börsentäglich über 12.000 News
Drohnen, Robotik, E-Autos: Diese Hightech-Aktie könnte jetzt zünden
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 940602 | ISIN: NL0000009538 | Ticker-Symbol: PHI1
Tradegate
11.02.26 | 18:32
26,740 Euro
-3,26 % -0,900
1-Jahres-Chart
KONINKLIJKE PHILIPS NV Chart 1 Jahr
5-Tage-Chart
KONINKLIJKE PHILIPS NV 5-Tage-Chart
RealtimeGeldBriefZeit
26,80026,82018:40
26,79026,82018:39
GlobeNewswire (Europe)
869 Leser
Artikel bewerten:
(2)

Royal Philips: Philips and Ibex expand partnership to enhance AI-enabled pathology workflows for better patient care

March 24, 2025

Interoperable AI-powered digital pathology workflows support confident cancer diagnosis

Amsterdam, The Netherlands -Royal Philips, Philips and Ibex can now offer even further interoperability of its solutions, aiming to enhance diagnostic workflows for clinicians and enabling better care for more people.

Enhanced Diagnostic Accuracy and Efficiency
Ibex's AI and Philips' digital pathology solution have shown to improve reporting efficiency and drive productivity gains of up to 37% [1]. Through this partnership, pathology laboratories are able to utilize PIPS, which includes the full portfolio of scanners and Image Management System, and Ibex's platform of AI-powered tools for prostate, breast and gastric cancer diagnostics.

Expanding access and streamlining the use of AI-powered tools in digital pathology will further enhance the efficiency and effectiveness of pathology labs. Enabling AI directly in digital pathology workflows empowers clinicians to generate objective, reproducible results, increasing diagnostic confidence and enabling the productivity improvements needed to address the growing demand for pathology-based diagnostics.

"Pathology provides key information for a precise diagnosis. The Philips and Ibex solutions are especially beneficial to the diagnosis of cancer cases because they aid our pathologists in making an accurate and quick diagnosis," said Sam Terese, President & CEO of Alverno Laboratories. "These integrated pathology solutions help us provide the highest possible quality result that any lab can deliver, getting answers back to our clinicians quickly and saving patients sleepless nights, even on complex cases."

By further integrating Ibex's AI with PIPS, the solutions can offer optimized workflows, including help with case prioritization, AI-powered cancer detection and reporting, providing easier integration of productivity enhancing tools for more confident diagnosis, supporting better patient care.

Improved features and Cloud Archiving
Philips is also introducing Philips IntelliSite Pathology 6.0, including several new features and AI capabilities [2] into the system. By providing advanced analysis and insights based on the context of the scanned images, pathology teams can access a seamless, AI-powered [2] clinical workflow solution, from case management through to diagnosis and reporting.

"The enhanced interoperability between Philips and Ibex platforms, which are now more seamlessly integrated into our diagnostic workflows, will accelerate the adoption of augmented pathology tools in which we strongly believe," said Stéphane Rossat, Innovation & Scientific Director and Project Management at Medipath. "PIPS 6.0 promises to facilitate adoption by our physicians, thanks to its streamlined navigation and optimized workflows.
We are eager to contribute to the evolution toward true digital "cockpits," which will become the reference interface for our pathologists."

PIPS 6.0 features improved workflows and enhancements including full scan mode for the pathology SG scanner and contextual launch of AI [2] and counter marker tool in the image management system, as well as improved scalability. AI focused worklists show AI processing status at a case level and slides can automatically be shared with Ibex AI applications, for processing right after digitization. This new version of the Philips digital pathology solution offers optimized workflows, designed to enhance the efficiency and improved patient care.

Based on Philips' collaboration with Amazon Web Services, offerings for cloud archival services will allow pathology labs to efficiently and securely store, manage, and analyze growing volumes of digital pathology data. For further information on Philips' full digital pathology portfolio, please visit hereand which will also be showcased at the US & Canadian Academy of Pathology (USCAP) Annual Conference in Boston March 24-27, 2025.

[1] Information provided by Ibex AI: Raoux, et al. Modern Pathology (2021) 34 (suppl 2): 598-599. Ibex AI is RUO in the US.
[2] PIPS enables iSyntax files and with the Software Development Kit (SDK) third-party companies can use this for AI capabilities. PIPS 6.0 contextual launch of Ibex AI is RUO in the US.

For further information, please contact:

Anna Hogrebe
Philips Global External Relations
Tel.: +1 416 270 6757
E-mail: anna.hogrebe@philips.com

About Royal Philips

Royal Philips.

Attachments

  • Review of results in PIPS 6 with Ibex AI launched (https://ml-eu.globenewswire.com/Resource/Download/10cfdae5-6c08-440a-93ed-0d7efaee8ddd)
  • PIPS 6.0 with Ibex AI (https://ml-eu.globenewswire.com/Resource/Download/62ba876f-3c24-41db-ab19-2708c3bd4f0d)
  • Pathologist and PIPS 6.0 with Ibex AI (https://ml-eu.globenewswire.com/Resource/Download/d383ce5f-9e64-4753-a873-cf92318969bf)

© 2025 GlobeNewswire (Europe)
Favoritenwechsel
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.